Mark Berger

4 Patents

• US125393402026

  Radioconjugates Targeting CD33 in the Treatment of Cancers

  0 cites
• US124912742025

  Radioconjugates Targeting CD33 in the Treatment of Sarcomas

  0 cites
• US120831922024

  Methods for Treatment of Patients with Myelodysplastic Syndromes

  Actinium Pharmaceuticals, Inc.

  0 cites
• US119127802024

  Anti-cd45-based Conditioning Methods and Uses Thereof in Conjunction with Gene-edited Cell-based Therapies

  ACTINIUM PHARMACEUTICALS, Inc.

  0 cites